Transform your PDFs into Flipbooks and boost your revenue!
Leverage SEO-optimized Flipbooks, powerful backlinks, and multimedia content to professionally showcase your products and significantly increase your reach.
<strong>EULAR</strong> <strong>2024</strong><br />
Congress Preview<br />
Psoriatic Arthritis<br />
Faculty Introduction<br />
Dear Colleagues,<br />
Welcome to this year’s selection of <strong>EULAR</strong> abstracts on psoriatic arthritis and my ‘<strong>Highlights</strong>’. We have selected a variety of abstracts<br />
that cover a range of key topics in the management of psoriatic arthritis.<br />
To begin the congress on Wednesday, Beatriz Joven-Ibáñez presents an evaluation of the risk of <strong>PsA</strong> in patients with psoriasis<br />
undergoing biological treatment in a global population, with data from the TRINTEX study (OP0010).<br />
Thursday offers a fantastic range of options for attendees starting with two talks on emerging therapies for the treatment of <strong>PsA</strong>. Alan Kivitz<br />
presents efficacy and safety outcomes with TAK-279 from a Phase 2b trial (OP0138), and this is followed by a talk on Phase 2 results for the<br />
novel IL-17A and IL-17F inhibitor sonelokimab by <strong>IMID</strong> Forum Chair Iain McInnes (OP0195). After these, there is a session celebrating the<br />
50th Anniversary of Moll and Wright’s landmark paper, where I will review recent insights into the pathogenesis and treatment of <strong>PsA</strong> today.<br />
On Friday, the session Poster View V provides a great number of new insightful presentations on a range of therapies. Fellow Steering<br />
Committee member Philip Mease and I will discuss developments for the IL-23 inhibitor guselkumab, looking at durable improvements<br />
in pain in TNFi inadequate responders from the COSMOS trial (POS0943) and on-label treatment persistence compared with IL-17A<br />
inhibitors in <strong>PsA</strong> patients from routinely collected US claims data (POS0984).<br />
Upadacitinib is also well represented this year with Philipp Sewerin discussing sustainability of response using Week 152 data from the<br />
SELECT trials (POS0945), and Stephanie Werner presenting data on real-world use and impact on MDA in patients with oligo- and<br />
poly-articular <strong>PsA</strong> from the UPJOINT study (POS0967). In another study in patients with oligo-articular <strong>PsA</strong>, Laure Gossec will discuss<br />
apremilast treatment for improved clinical and patient-reported outcomes in patients with early oligoarthritic disease (POS0976).<br />
Here, efficacy is demonstrated with significantly more patients on apremilast experiencing minimal disease activity with fewer patients<br />
progressing from 4, indicating a progression from oligoarthritis to polyarthritis – this is one you won’t want to miss.<br />
Furthermore, we have important results on the use of deucravacitinib, ixekizumab, and bimekizumab in clinical practice. Philip Mease<br />
will present results from a Phase 2 trial of the TYK2 inhibitor deucravacitinib in patients with active <strong>PsA</strong> and enthesitis (POS0957),<br />
and I will be highlighting improved clinical outcomes with ixekizumab irrespective of erosion number at baseline (POS0950).<br />
Finally, my colleagues and I will report sustained achievement of MDA with bimekizumab in <strong>PsA</strong> patients over 2-years (POS0969).<br />
This year is set to be another fantastic congress, I look forward to seeing you all in Vienna, where we will continue to push the<br />
boundaries of the clinical management of <strong>PsA</strong>.<br />
As always, thank you for your continued support. We hope you have a fantastic time at <strong>EULAR</strong> <strong>2024</strong>!<br />
Kind regards,<br />
Laura Coates<br />
P.S. To ensure you get all the insights from this <strong>EULAR</strong>, download our other highlights brochures on RA and axSpA. If you want to<br />
see the top picks for Lupus, visit www.lupus-forum.com where you’ll find expert-selected sessions and their abstracts in the field of<br />
lupus therapeutics.<br />
Register for<br />
FREE content at<br />
imidforum.com<br />
DATE OF PREPARATION: JUNE <strong>2024</strong><br />
Follow us on:<br />
Immune-Mediated<br />
Inflammatory<br />
Disease Forum<br />
SPONSORSHIP AND UNRESTRICTED<br />
EDUCATIONAL GRANTS FROM<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ORAL SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
Key Presentations<br />
Wednesday, June 12, <strong>2024</strong><br />
14:15 –<br />
15:30<br />
14:30 –<br />
15:15<br />
16:30 –<br />
18:00<br />
OP0010<br />
JAK INHIBITOR SPECIAL WARNINGS: CAN<br />
OBSERVATIONAL DATA DEBUNK AN RCT?<br />
Chairs: Kim Lauper and John Cush<br />
Speakers: Janet Pope and David Liew<br />
CAR T-CELLS TO TREAT RMDS<br />
Chairs: Christophe Richez and Anastasia Madenidou<br />
CAR T-cell therapy for inflammatory RMDs<br />
Georg Schett<br />
CLINICAL ABSTRACT SESSIONS: TREATING<br />
CLINICAL ASPECTS OF SPA AND PSA<br />
Chairs: Sofia Ramiro and Helena Marzo-Ortega<br />
Evaluation of the risk of psoriatic arthritis in patients<br />
with psoriasis undergoing biological treatment.<br />
Global population study (TRINETX)<br />
Beatriz Joven-Ibáñez<br />
14:45 –<br />
15:45<br />
POS0894<br />
POS0911<br />
14:45 –<br />
15:45<br />
POS0231<br />
POSTER VIEW IV<br />
Safety of upadacitinib across rheumatoid arthritis,<br />
psoriatic arthritis, and axial spondyloarthritis encompassing<br />
15,000 patient-years of clinical trial data<br />
Gerd R. Burmester<br />
Reasons for non-response to treatment in patients with<br />
rheumatoid arthritis, ankylosing spondylitis and psoriatic<br />
arthritis classified as Difficult to Treat (D2T)<br />
Fulya Cosan<br />
CLINICAL POSTER TOURS:<br />
TREATMENT OF SPONDYLOARTHRITIS<br />
Chairs: Nikolaos Kougas and Augusta Ortolan<br />
Comparative safety of JAK inhibitors versus TNF or<br />
IL-17 inhibitors for cardiovascular disease, venous<br />
thromboembolism and cancer in psoriatic arthritis and<br />
axial spondyloarthritis<br />
Sizheng Steven Zhao<br />
Thursday, June 13, <strong>2024</strong><br />
10:30 –<br />
12:00<br />
OP0138<br />
OP0150<br />
OP0195<br />
13:30 –<br />
14:45<br />
CLINICAL ABSTRACT SESSIONS:<br />
SPA & PSA – TREATMENT EFFECTS AND<br />
RESPONSE PREDICTION<br />
Chairs: Krystel Aouad and Adrian Ciurea<br />
Efficacy and safety outcomes of TAK-279, a H<br />
selective oral tyrosine kinase 2 (TYK2) inhibitor,<br />
from a randomized, double-blind, placebo-controlled<br />
Phase 2b trial in patients with active psoriatic arthritis<br />
Alan Kivitz<br />
Risk of non-melanoma skin cancer with TNFi and other<br />
bDMARDs in patients with psoriatic arthritis: A Swedish<br />
and Danish cohort study<br />
Rasmus Westermann<br />
Efficacy and safety of sonelokimab, a novel<br />
IL-17A- and IL-17F-inhibiting Nanobody ® , in<br />
patients with active psoriatic arthritis (<strong>PsA</strong>):<br />
Results from the global, randomized, double-blind,<br />
placebo-controlled Phase 2 ARGO trial<br />
Iain B. McInnes<br />
THERAPEUTIC DRUG MONITORING OF<br />
TNF INHIBITORS: TO MONITOR OR NOT?<br />
Chairs: John Isaacs and Gerrit Jan Wolbink<br />
Speakers: Silje Watterdal Syversen and Désirée van<br />
der Heijde<br />
H<br />
Friday, June 14, <strong>2024</strong><br />
09:30 –<br />
10:30<br />
POS0943<br />
POS0945<br />
POS0950<br />
POS0953<br />
POS0954<br />
POS0957<br />
POSTER VIEW V<br />
Guselkumab provides durable improvements in H<br />
pain among patients with psoriatic arthritis and an<br />
inadequate response to TNFi: COSMOS Phase 3b trial<br />
Laura C. Coates<br />
Sustainability of response with upadacitinib<br />
in patients with moderately to severely active<br />
psoriatic arthritis: Week 152 data from the<br />
SELECT-<strong>PsA</strong> 1 and SELECT-<strong>PsA</strong> 2 trials<br />
Philipp Sewerin<br />
Irrespective of the number of erosions at<br />
baseline, patients with psoriatic arthritis treated<br />
with ixekizumab show improved clinical outcomes<br />
Laura C. Coates<br />
Comparing long-term persistence rates of secukinumab or<br />
adalimumab using propensity score matching in patients with<br />
psoriatic arthritis: Findings from the real-world flyway study<br />
Hideto Kameda<br />
The impact of smoking status on one-year secukinumab<br />
retention rate in 1,684 patients with psoriatic arthritis:<br />
Real-world results from the EuroSpA collaboration<br />
Stylianos Georgiadis<br />
Effect of deucravacitinib, an oral, selective,<br />
allosteric tyrosine kinase 2 (TYK2) inhibitor, in<br />
patients with active psoriatic arthritis (<strong>PsA</strong>) and<br />
enthesitis at baseline: Results from a Phase 2 trial<br />
Phillip J. Mease<br />
H<br />
H<br />
H
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ORAL SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
POS0961<br />
POS0963<br />
POS0967<br />
POS0969<br />
POS0972<br />
POS0976<br />
POS0977<br />
POS0978<br />
POS0981<br />
POS0983<br />
POS0984<br />
Bimekizumab maintained efficacy responses through<br />
52 weeks in patients with active psoriatic arthritis:<br />
Results from two Phase 3 studies<br />
William Tillett<br />
Impact of risankizumab on enthesitis and dactylitis by<br />
location and baseline severity in patients with psoriatic<br />
arthritis from the KEE<strong>PsA</strong>KE 1 and KEE<strong>PsA</strong>KE 2 trials<br />
Dennis McGonagle<br />
Real-World use of upadacitinib and impact on<br />
minimal disease activity in patients with oligoor<br />
poly-articular psoriatic arthritis: Data from the<br />
UPJOINT study<br />
Stephanie Werner<br />
Bimekizumab-treated patients with active<br />
psoriatic arthritis showed sustained achievement<br />
of minimal disease activity and remission: Up to<br />
2-year results from two Phase 3 studies<br />
Laura C. Coates<br />
Relationships between inhibition of radiographic<br />
progression and achievement of low disease activity or<br />
remission and their core components in patients with<br />
psoriatic arthritis treated with secukinumab over 2 years<br />
in FUTURE 5<br />
Philip J. Mease<br />
Apremilast treatment in early oligoarticular<br />
psoriatic arthritis (<strong>PsA</strong>) improves clinical and<br />
patient-reported outcomes for up to 48 weeks –<br />
Data from the FOREMOST study<br />
Laure Gossec<br />
Effects of secukinumab on enthesophyte and erosion<br />
progression in psoriatic arthritis – a 48-week placebocontrolled<br />
double-blinded RCT utilizing high-resolution<br />
peripheral quantitative computed tomography (HR-pQCT)<br />
Isaac T. Cheng<br />
Direct and indirect effects of upadacitinib or adalimumab<br />
on pain in psoriatic arthritis: Results from a randomized<br />
Phase 3 study<br />
Peter C. Taylor<br />
Analyzing outcomes in psoriatic arthritis: A comparative<br />
study between JAK inhibitors and interleukin 17 inhibitors<br />
Rafal Ali<br />
Pooled analysis of three Phase 3, randomized, doubleblind,<br />
placebo-controlled studies to longitudinally evaluate<br />
the novel psoriatic arthritis 5-thermometer scale (psa-5ts)<br />
domains during guselkumab treatment<br />
Carlo Selmi<br />
Comparison of on-label treatment persistence in<br />
real-world patients with psoriatic arthritis receiving<br />
guselkumab versus subcutaneous IL-17A inhibitors<br />
Philip J. Mease<br />
H<br />
H<br />
H<br />
H<br />
9:30 –<br />
10:30<br />
POS0266<br />
13:30 –<br />
14:45<br />
CLINICAL POSTER TOURS: CLINICAL<br />
ASPECTS OF PSORIATIC ARTHRITIS<br />
Chairs: Nikolaos Kougas and Clementina López-Medina<br />
Cycling vs swap TNFi and IL17i in psoriatic arthritis:<br />
Results from the BIRRA retrospective observational study<br />
Simone Parisi<br />
DISCOVERY IN JOINT AND SKIN DISEASE:<br />
A FOR(E)UM ON PSORIATIC ARTHRITIS<br />
Chairs: Nuria Barbarroja and Rik Lories<br />
Speakers: Rik Lories, Erik Lubberts,<br />
Mariola Kurowska-Stolarska, and Marietta Armaka<br />
Saturday, June 15, <strong>2024</strong><br />
09:00 –<br />
10:00<br />
LBA0002<br />
LBA0005<br />
ORAL ABSTRACT SESSIONS:<br />
LATE-BREAKING ABSTRACTS<br />
Chairs: Denis Poddubnyy and Bimba Franziska Hoyer<br />
Early (3-month) and maintained (12-month) comparative<br />
effectiveness of 5 different classes of advanced therapies<br />
in a large multinational cohort of real-world <strong>PsA</strong> patients<br />
Dennis McGonagle<br />
Efficacy and safety of izokibep, a novel IL-17A inhibitor,<br />
in patients with active psoriatic arthritis: Week 16 results<br />
from a randomized, double-blind, placebo-controlled,<br />
multicenter Phase 2b/3 study<br />
Philip J. Mease
KEY:<br />
H<br />
<strong>Highlights</strong><br />
ORAL SESSION<br />
POSTER SESSION<br />
SCIENTIFIC SESSION<br />
Satellite Symposia<br />
WEDNESDAY, JUNE 12, <strong>2024</strong><br />
18:30 –<br />
19:45<br />
The great quest for disease control in <strong>PsA</strong><br />
Sponsor: AbbVie<br />
Chair: Iain B. McInnes<br />
Speakers: Iain B. McInnes, Laura Coates, and Lihi Eder<br />
THURSDAY, JUNE 13, <strong>2024</strong><br />
08:15 –<br />
09:30<br />
08:15 –<br />
09:30<br />
17:30 –<br />
18:45<br />
17:30 –<br />
18:45<br />
What makes deucravacitinib TYK?<br />
Sponsor: BMS<br />
Chair: Josef S. Smolen<br />
Speakers: Josef S. Smolen, Hendrik Schulze-Koops,<br />
Alberto Cauli, and Joan Merrill<br />
Revealing new layers: How targeting IL-17A<br />
is shaping rheumatic and musculoskeletal<br />
disease management<br />
Sponsor: Novartis<br />
Chair: Sofia Ramiro<br />
Speakers: Sofia Ramiro, Georg Schett, Helena Marzo-Ortega,<br />
and Wolfgang Schmidt<br />
The cycle of inflammation: IL-23 across<br />
psoriatic disease<br />
Sponsor: Johnson & Johnson<br />
Chairs: Andreas Kerschbaumer and Georg Schett<br />
Speakers: Andreas Kerschbaumer, Georg Schett,<br />
Alexander Moschen, Laura Savage, and Dennis McGonagle<br />
Time to revolutionise clinical practice? Striving for<br />
resolution of inflammation with the dual inhibition<br />
of IL-17A and IL-17F in <strong>PsA</strong> and axSpA<br />
Sponsor: UCB<br />
Chair: Iain B. McInnes<br />
Speakers: Maria-Antonietta D’Agostino, Martin Rudwaleit,<br />
and Iain B. McInnes<br />
FRIDAY, JUNE 14, <strong>2024</strong><br />
08:15 –<br />
09:30<br />
Anti-CD19 CAR T-Cell therapy in rheumatologic<br />
autoimmune diseases and beyond<br />
Sponsor: Kyverna<br />
Chair: Peter A. Merkel<br />
Speakers: Peter Maag, Peter A. Merkel, Roberto Caricchio,<br />
Gerhard Krönke, James Chung, and Richard A. Furie<br />
Register for<br />
FREE content at<br />
imidforum.com<br />
Follow us on:<br />
Immune-Mediated<br />
Inflammatory Disease Forum<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE
Change language